STAAR Surgical Co
NASDAQ:STAA

Watchlist Manager
STAAR Surgical Co Logo
STAAR Surgical Co
NASDAQ:STAA
Watchlist
Price: 25.38 USD -4.59% Market Closed
Market Cap: 1.3B USD

STAAR Surgical Co
Income from Continuing Operations

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

STAAR Surgical Co
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
STAAR Surgical Co
NASDAQ:STAA
Income from Continuing Operations
-$96.4m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
-28%
Haemonetics Corp
NYSE:HAE
Income from Continuing Operations
$168.2m
CAGR 3-Years
25%
CAGR 5-Years
10%
CAGR 10-Years
21%
ICU Medical Inc
NASDAQ:ICUI
Income from Continuing Operations
-$8.7m
CAGR 3-Years
39%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Align Technology Inc
NASDAQ:ALGN
Income from Continuing Operations
$378.6m
CAGR 3-Years
-10%
CAGR 5-Years
-26%
CAGR 10-Years
11%
Lantheus Holdings Inc
NASDAQ:LNTH
Income from Continuing Operations
$167.7m
CAGR 3-Years
16%
CAGR 5-Years
235%
CAGR 10-Years
N/A
Merit Medical Systems Inc
NASDAQ:MMSI
Income from Continuing Operations
$118.4m
CAGR 3-Years
24%
CAGR 5-Years
N/A
CAGR 10-Years
16%
No Stocks Found

STAAR Surgical Co
Glance View

Market Cap
1.3B USD
Industry
Health Care

In the early throes of medical innovation, STAAR Surgical Co. carved a niche within the ophthalmic industry, where its focus on implantable lenses set it apart from many contemporaries. Based in Monrovia, California, the company began its journey by enhancing an integral component of human life: vision. Through the skillful development and manufacture of implantable collamer lenses (ICLs), STAAR Surgical has thrived by providing solutions for those seeking alternatives to laser-based surgeries. Its ICL technology directly targets issues like myopia (nearsightedness) and astigmatism, offering patients a reversible, less invasive option than traditional corrective procedures. STAAR Surgical's business model hinges on a blend of specialized technology and strategic market penetration. The company primarily generates revenue by selling its suite of implantable lenses to healthcare providers and clinics worldwide, capitalizing on the rising trend of elective vision correction procedures. With its innovation-driven credo, STAAR continually invests in R&D to enhance its product offerings, ensuring it remains at the forefront of eye-care technology. By targeting emerging markets and expanding its global footprint, particularly in regions with growing demand for premium vision solutions, STAAR has positioned its unique value proposition to capitalize on both technological advancements and changing patient preferences. Through this deliberate strategy, STAAR not only bolsters its revenue streams but also fortifies its presence as a key player in the ophthalmic landscape.

STAA Intrinsic Value
15.73 USD
Overvaluation 38%
Intrinsic Value
Price

See Also

What is STAAR Surgical Co's Income from Continuing Operations?
Income from Continuing Operations
-96.4m USD

Based on the financial report for Sep 26, 2025, STAAR Surgical Co's Income from Continuing Operations amounts to -96.4m USD.

What is STAAR Surgical Co's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
-28%

Back to Top